亚洲与非亚洲脑出血患者临床结局差异:降压试验个体数据汇总分析
该研究基于16项急性脑出血降压治疗随机对照试验的个体数据,比较亚洲(主要为东亚和南亚)与非亚洲患者的临床结局。经混杂因素调整后,亚洲患者90天死亡或依赖、主要残疾及7天内神经功能恶化的风险显著低于非亚洲患者,但24小时血肿扩大和90天死亡无显著差异,且降压治疗与地区无显著交互作用。
要点
- 亚洲脑出血患者90天死亡或依赖风险显著低于非亚洲患者(IPTW OR 0.67)。
- 亚洲患者7天内神经功能恶化风险亦较低(IPTW OR 0.70)。
- 24小时血肿扩大和90天死亡在地区间无显著差异。
核心结论
- 经混杂调整后,东亚和南亚脑出血患者功能恢复更优且神经功能恶化风险更低,但24小时血肿扩大无地区差异。
研究设计与样本
- 基于血压急性卒中协作组脑出血数据集的观察性分析,汇总16项完成的高血压降压治疗随机对照试验的个体参与者数据。
- 共纳入6221例患者,年龄63.3±13.0岁,女性占36.4%,其中3494例(56.2%)来自亚洲。
- 采用广义线性混合模型和逆概率治疗加权(IPTW)分析地区与临床结局的关联。
主要发现
- 亚洲患者90天死亡或依赖风险低于非亚洲患者:未调整OR 0.44(95%CI 0.39–0.51),IPTW加权OR 0.67(95%CI 0.58–0.77)。
- 亚洲患者90天主要残疾风险较低:未调整OR 0.49(95%CI 0.42–0.56),IPTW加权OR 0.67(95%CI 0.57–0.78)。
- 亚洲患者7天内神经功能恶化风险较低:未调整OR 0.63(95%CI 0.52–0.77),IPTW加权OR 0.70(95%CI 0.56–0.89)。
- 24小时血肿扩大(P=0.97)和90天死亡(P=0.23)在IPTW分析中无显著地区差异。
- 降压治疗与地区(亚洲 vs 非亚洲)对所有结局均无显著交互作用(IPTW分析)。
关键数值与推荐
- 神经功能恶化定义为7天内发生。
- 血肿扩大定义为24小时时绝对增加≥6 mL或相对增加≥33%。
- 死亡或依赖定义为90天改良Rankin量表评分3–6分。
- 主要残疾定义为90天改良Rankin量表评分3–5分。
临床怎么用
- 临床评估脑出血预后时应考虑地区差异,亚洲患者功能结局可能优于非亚洲患者。
- 早期强化降压治疗对不同地区患者的疗效无显著异质性,可统一应用。
- 未来脑出血研究设计需纳入地区因素以控制混杂。
局限性
- 为观察性分析,尽管采用IPTW调整混杂,仍可能存在未测量混杂。
- 亚洲人群以东亚和南亚为主,结果外推至其他亚洲地区需谨慎。
- 仅纳入参与降压治疗随机对照试验的患者,选择偏倚可能存在。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Stroke, Ahead of Print. BACKGROUND:Evidence of regional differences in clinical outcomes after intracerebral hemorrhage (ICH) is still scarce. We quantified differential outcomes and response to early intensive blood pressure lowering treatment by region in the Blood pressure in Acute Stroke Collaboration ICH data set.METHODS:This was an observational analysis of pooled individual participant data from 16 completed randomized controlled trials of blood pressure-lowering treatment in acute ICH, based on the Blood pressure in Acute Stroke Collaboration data set. Generalized linear mixed models with inverse probability of treatment weighting (IPTW) were used to determine the association between regions (Asia [primarily East and South Asia] versus non-Asia) and clinical outcomes including neurological deterioration within 7 days, hematoma expansion at 24 hours (absolute ≥6 mL or relative ≥33%), and death or dependency (modified Rankin Scale scores, 3–6), major disability(modified Rankin Scale score, 3–5), death alone at 90 days.RESULTS:Among 6221 patients (age, 63.3±13.0 years; female 36.4%), 3494 (56.2%) were from Asia. ICH participants from Asia had a significantly reduced risk of death or dependency (unadjusted odds ratio [OR], 0.44 [95% CI, 0.39–0.51]; IPTW-weighted OR, 0.67 [95% CI, 0.58–0.77]); and major disability (unadjusted OR, 0.49 [95% CI, 0.42–0.56]; IPTW-weighted OR, 0.67 [95% CI, 0.57–0.78]) at 90 days, neurological deterioration (unadjusted OR, 0.63 [95% CI, 0.52–0.77]; IPTW-weighted OR, 0.70 [95% CI, 0.56–0.89]) within 7 days, in comparison to those from non-Asia regions. However, there were no differences for hematoma expansion (P=0.97) at 24 hours or death (P=0.23) at 90 days using IPTW. Additionally, there were no significant interactions between blood pressure–lowering treatment and region (Asia versus non-Asia) for either outcome using IPTW.CONCLUSIONS:Participants from East and South Asia had a favorable functional recovery and a lower risk of neurological deterioration compared with those from non-Asian regions after adjustment for confounders, with no differences in hematoma expansion at 24 hours after ICH. These findings suggest that future ICH studies on clinical outcomes should consider regional differences.
引用
- Stroke:Clinical Outcome Differences in Asia Versus Non-Asia Intracerebral Hemorrhage: IPD Analysis From BP-Lowering Clinical Trials
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。